of clarithromycin for the treatment of M. avium complex disease is reported (1) . Clarithromycin is considered to be effective for the treatment of M. avium complex infections. However,clarithromycin resistance develops in patients receiving clarithromycin alone. Therefore, combined therapy is required to treat M. avium complex infection.
See also p 670.
Official statement of the American Thoracic Society is that initial therapy for adult HIV-negative patients with M. avium complex disease needing treatment should consist of a minimumthree-drug regimen of clarithromycin (500 mg twice a day) or azithromycin (250 mg/day or 500 mg three times a week), rifabutin (300 mg/day) or rifampin (600 mg/ day), and ethambutol (25 mg/kg per day for 2 months followed by 15 mg/kg per day). For patients of small body mass and/or an age over 70, clarithromycin at 250 mg twice a day or azithromycin 250 mg three times a week may be better tolerated (2) . A nationwide study was conducted in Japan to investigate the efficacy of clarithromycin on pulmonary atypical mycobacteriosis caused by M. avium complex and concluded that at a daily dose of clarithromycin of 600 mg or higher was effective in the elimination or reduction of M. avium complex without the development of serious side effects (3). And the Japanese Society for Tuberculosis recommendsthe combination therapy consisting of clarithromycin, rifampicin, ethambutol and aminoglycoside (4). However, clarithromycin is approved only for the treatment of bacteremia due to M. avium complex in acquired immunodeficiency syndrome (AIDS) patients in Japan.
The best dose regimen of clarithromycin is unclear. Not more than 500 mg twice daily should be given. Azithromycin is an alternative to clarithromycin, although the optimal dose schedule for azithromycin remains unclear and is also under study. Rifabutin is the preferred rifamycin because it is more active in vivo than rifampicin against M. avium complex. In addition rifampicin appears to have more potential for drug interactions. However,we cannot obtain rifabutin in Japan. In a case of HIV infection, drug interactions with the protease inhibitors should be considered. Intermittent streptomycin for the first 2 to 3 months of therapy maybe considered, in addition to the above regimen, for extensive disease (2). The exact dose of streptomycin in this multidrug regimen will depend on the patient's age and weight. For extensive disease, at least 2 months of intermittent (twice or three times weekly) streptomycin is recommend, although longer therapy with streptomycin may be desirable in patients with very extensive disease or for those who do not tolerate other agents (2) . There is no data, however, comparing clarithromycin-containing regimens with
and without an aminoglycoside. The patient and physician should be alert to signs and symptomsof streptomycin toxicity, and these may prevent completion of the full course of therapy. Because ototoxicity due to streptomycin is often irreversible, patients receiving streptomycin should be instructed in the signs and symptoms of toxicity at the start of therapy and again on subsequent visits, with discontinuation or decrease in dosage or frequency if suggestive signs of toxicity occur. The optimal length of drug therapy for M. avium complex lung disease has not been established. With macrolides, a shorter length of therapy seems acceptable. Long-term studies of M. avium complex lung disease have been reported (5, 6) , and suggest that culture negativity of 10 to 12 months is adequate for most patients.
Acid-fast bacilli (AFB) smears and cultures of sputum should be obtained monthly during therapy for pulmonary M.
avium complex disease to assess response, and then periodically after completion of therapy to evaluate possible relapse. The desired endpoint is negative sputum cultures; patients who respond to therapy should develop negative AFB smears and cultures. One or more cultures containing small numbers of M. avium complex organisms (single colonies on solid media or positive liquid media cultures only) may occur after sputum conversion and should not necessarily be interpreted as indicative of treatment failure or relapse.
Rather, these culture results should be interpreted in light of the patient's overall clinical status.
